KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) shares reached a new 52-week high during trading on Tuesday after Leerink Partners raised their price target on the stock from $18.00 to $20.00. Leerink Partners currently has an outperform rating on the stock. KalVista Pharmaceuticals traded as high as $15.91 and last traded at $15.06, with a volume of 11289568 shares changing hands. The stock had previously closed at $11.98.
Other equities analysts have also recently issued research reports about the company. Needham & Company LLC restated a "buy" rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Finally, Jones Trading reissued a "buy" rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, KalVista Pharmaceuticals presently has an average rating of "Buy" and an average price target of $24.14.
Check Out Our Latest Stock Report on KALV
Insider Activity
In related news, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The shares were acquired at an average cost of $9.42 per share, with a total value of $235,500.00. Following the transaction, the insider owned 5,303,985 shares of the company's stock, valued at $49,963,538.70. The trade was a 0.47% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Benjamin L. Palleiko sold 7,169 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $14.50, for a total transaction of $103,950.50. Following the completion of the sale, the chief executive officer directly owned 315,074 shares in the company, valued at $4,568,573. This represents a 2.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,899 shares of company stock worth $206,176 in the last 90 days. Corporate insiders own 10.50% of the company's stock.
Institutional Trading of KalVista Pharmaceuticals
A number of institutional investors have recently made changes to their positions in KALV. AlphaQuest LLC lifted its position in KalVista Pharmaceuticals by 17.1% during the 4th quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock worth $150,000 after buying an additional 2,588 shares in the last quarter. Intech Investment Management LLC raised its holdings in KalVista Pharmaceuticals by 58.5% during the fourth quarter. Intech Investment Management LLC now owns 17,204 shares of the specialty pharmaceutical company's stock worth $146,000 after acquiring an additional 6,349 shares in the last quarter. Vanguard Group Inc. raised its holdings in KalVista Pharmaceuticals by 4.9% during the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company's stock worth $19,102,000 after acquiring an additional 104,716 shares in the last quarter. Schroder Investment Management Group raised its holdings in KalVista Pharmaceuticals by 86.8% during the fourth quarter. Schroder Investment Management Group now owns 805,445 shares of the specialty pharmaceutical company's stock worth $6,758,000 after acquiring an additional 374,213 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of KalVista Pharmaceuticals by 4.2% during the 4th quarter. Wellington Management Group LLP now owns 122,863 shares of the specialty pharmaceutical company's stock worth $1,041,000 after purchasing an additional 4,940 shares in the last quarter.
KalVista Pharmaceuticals Trading Up 25.7%
The company has a market cap of $748.78 million, a P/E ratio of -4.05 and a beta of -0.04. The business has a 50 day moving average price of $12.43 and a 200-day moving average price of $11.08.
About KalVista Pharmaceuticals
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
